Clinical Outcomes of Pyrocarbon Hemiarthroplasty
Journal of Bone and Joint Surgery · 15.04.2026 · 108 (8) · 572-583
DOI: 10.2106/jbjs.25.00054 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Bone and Joint Surgery, online erschienen am 29.12.2025. Verfasst von Armodios M Hatzidakis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Western Orthopaedics, Denver, Colorado. Hauptthemen laut MEDLINE: Hemiarthroplasty, Carbon, Arthroplasty, Replacement, Shoulder, Shoulder Prosthesis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Background
Unacceptable pain relief after hemiarthroplasty (HA) has limited its utilization for shoulder replacement. The material properties of pyrolytic carbon-graphite composites may result in less abrasion compared with metal bearing surfaces, theoretically decreasing glenoid-sided pain and erosion. This prospective, single-arm, multicenter study was performed to evaluate the short-term clinical outcomes and implant survivorship of pyrocarbon HA.
Methods
The enrollment of 157 patients occurred at 18 sites between December 2015 and April 2017 as part of an Investigational Device Exemption protocol. The Constant score, American Shoulder and Elbow Surgeons (ASES) score, Single Assessment Numeric Evaluation (SANE) score, patient satisfaction, EuroQol-5 Dimensions (EQ-5D) score, and active range of motion were evaluated. A historical control cohort treated with cobalt-chromium HA was identified through a propensity score subclassification analysis. The pyrocarbon HA and cobalt-chromium HA cohorts were compared on the basis of a Composite Clinical Success (CCS) rate, defined as a ≥17-point change in the Constant score without revision or a device-related adverse event.
Results
Of the 157 patients enrolled, 144 had short-term follow-up (mean, 24.4 ± 1.2 months), 10 were lost to follow-up, and 3 underwent revision prior to 24 months due to pain or low-grade infection. The mean patient age was 52.4 ± 10.9 years (range, 19 to 73 years). There were significant improvements in all active range-of-motion and patient-reported outcomes. The outcomes of the pyrocarbon HA cohort (n = 157) were compared with those of the cobalt-chromium HA group (n = 169) eligible for a minimum 24-month follow-up, in which multiple imputation was employed to address missing data. The CCS was 82.7% for the pyrocarbon HA group and 66.8% for the cobalt-chromium HA group (p < 0.001).
Conclusions
Pyrocarbon HA demonstrated favorable results at a short-term follow-up and improved outcomes compared with the propensity score subclassification-derived cobalt-chromium HA cohort. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Western Orthopaedics, Denver, Colorado.
- Midwest Orthopaedics at Rush, Chicago, Illinois.
- Stryker, Amsterdam, The Netherlands.
- Stryker, Bloomington, Minnesota.
- Centers for Advanced Orthopaedics, Leonardtown, Maryland.
ORCID-Profile: Armodios M Hatzidakis, Grant E Garrigues, Libby A Mauter, Arthur de Gast, You Yang, Peter S Johnston
Zitieren
APA
Hatzidakis, A. M., Garrigues, G. E., Mauter, L. A., de Gast, A., Venegoni, M. R., Yang, Y., & Johnston, P. S. (2026). Clinical Outcomes of Pyrocarbon Hemiarthroplasty. Journal of Bone and Joint Surgery, 108(8), 572-583. https://doi.org/10.2106/jbjs.25.00054
Vancouver
Hatzidakis AM, Garrigues GE, Mauter LA, de Gast A, Venegoni MR, Yang Y, et al. Clinical Outcomes of Pyrocarbon Hemiarthroplasty. Journal of Bone and Joint Surgery. 2026;108(8):572-583. doi:10.2106/jbjs.25.00054
BibTeX
@article{Hatzidakis2026,
author = {Hatzidakis, Armodios M and Garrigues, Grant E and Mauter, Libby A and de Gast, Arthur and Venegoni, Matthew R and Yang, You and Johnston, Peter S},
title = {Clinical Outcomes of Pyrocarbon Hemiarthroplasty},
journal = {Journal of Bone and Joint Surgery},
year = {2026},
volume = {108},
number = {8},
pages = {572--583},
doi = {10.2106/jbjs.25.00054}
}
EUVIMED